CStone's China NDA for Anti-PD-L1 Candidate Accepted for Review

Suzhou CStone Pharma reported China 's NMPA accepted for review its NDA for sugemalimab, an anti-PD-L1 mAb, as a first-line therapy for non-small cell lung cancer. The regimen combines sugemalimab with chemotherapy for advanced squamous and non-squamous forms of NSCLC. It is the first NDA for the anti-PD-L1 candidate submitted by CStone worldwide, the sixth CStone NDA worldwide, and its third  China submission this year. CStone develops novel immunoncology therapies and precision medicines. More details.... Stock Symbol: (HK: 2616) Share this with colleagues: // //